Identifying potential treatments of COVID-19 from Traditional Chinese Medicine (TCM) by using a data-driven approach.
COVID-19
Chinese medicine (CM)
Data mining
Molecular docking
Network pharmacology
Journal
Journal of ethnopharmacology
ISSN: 1872-7573
Titre abrégé: J Ethnopharmacol
Pays: Ireland
ID NLM: 7903310
Informations de publication
Date de publication:
10 Aug 2020
10 Aug 2020
Historique:
received:
28
03
2020
revised:
24
04
2020
accepted:
27
04
2020
pubmed:
8
5
2020
medline:
5
6
2020
entrez:
8
5
2020
Statut:
ppublish
Résumé
Traditional Chinese Medicine (TCM) has been widely used as an approach worldwide. Chinese Medicines (CMs) had been used to treat and prevent viral infection pneumonia diseases for thousands of years and had accumulated a large number of clinical experiences and effective prescriptions. This research aimed to systematically excavate the classical prescriptions of Chinese Medicine (CM), which have been used to prevent and treat Pestilence (Wenbing, Wenyi, Shiyi or Yibing) for long history in China, to obtain the potential prescriptions and ingredients to alternatively treat COVID-19. We developed the screening system based on data mining, molecular docking and network pharmacology. Data mining and association network were used to mine the high-frequency herbs and formulas from ancient prescriptions. Virtual screening for the effective components of high frequency CMs and compatibility Chinese Medicine was explored by a molecular docking approach. Furthermore, network pharmacology method was used to preliminarily uncover the molecule mechanism. 574 prescriptions were obtained from 96,606 classical prescriptions with the key words to treat "Warm diseases (Wenbing)", "Pestilence (Wenyi or Yibing)" or "Epidemic diseases (Shiyi)". Meanwhile, 40 kinds of CMs, 36 CMs-pairs, 6 triple-CMs-groups existed with high frequency among the 574 prescriptions. Additionally, the key targets of SARS-COV-2, namely 3CL hydrolase (Mpro) and angiotensin-converting enzyme 2(ACE2), were used to dock the main ingredients from the 40 kinds by the LigandFitDock method. A total of 66 compounds components with higher frequency were docked with the COVID-19 targets, which were distributed in 26 kinds of CMs, among which Gancao (Glycyrrhizae Radix Et Rhizoma), HuangQin (Scutellariae Radix), Dahuang (Rhei Radix Et Rhizome) and Chaihu (Bupleuri Radix) contain more potential compounds. Network pharmacology results showed that Gancao (Glycyrrhizae Radix Et Rhizoma) and HuangQin (Scutellariae Radix) CMs-pairs could also interact with the targets involving in immune and inflammation diseases. These results we obtained probably provided potential candidate CMs formulas or active ingredients to overcome COVID-19. Prospectively, animal experiment and rigorous clinic studies are needed to confirm the potential preventive and treat effect of these CMs and compounds.
Identifiants
pubmed: 32376368
pii: S0378-8741(20)31440-9
doi: 10.1016/j.jep.2020.112932
pmc: PMC7196535
pii:
doi:
Substances chimiques
Drugs, Chinese Herbal
0
Plant Extracts
0
Viral Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
112932Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.
Références
J Altern Complement Med. 2005 Feb;11(1):49-55
pubmed: 15750363
Chin J Integr Med. 2020 Apr;26(4):243-250
pubmed: 32065348
Oncotarget. 2017 Feb 28;8(9):14549-14569
pubmed: 28099904
J Ethnopharmacol. 2018 Dec 5;227:155-165
pubmed: 30145173
J Med Virol. 2020 Apr;92(4):418-423
pubmed: 31967327
Sci Rep. 2017 Jan 11;7:40318
pubmed: 28074863
Am J Chin Med. 2019;47(6):1223-1235
pubmed: 31505937
Front Pharmacol. 2017 Oct 05;8:694
pubmed: 29051733
Nat Protoc. 2009;4(1):44-57
pubmed: 19131956
Zhongguo Zhong Yao Za Zhi. 2020 Mar;45(6):1213-1218
pubmed: 32281327
Biomed Pharmacother. 2019 Sep;117:109190
pubmed: 31387170
J Ethnopharmacol. 2020 Apr 24;252:112582
pubmed: 31972324
Genome Res. 2003 Nov;13(11):2498-504
pubmed: 14597658
Acta Pharm Sin B. 2016 May;6(3):212-21
pubmed: 27175332
BMC Bioinformatics. 2015 Oct 23;16:339
pubmed: 26493835
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
J Chem Inf Model. 2017 Mar 27;57(3):468-483
pubmed: 28257573